Drugs / SB208141
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00057330 | Jan 2003 → Aug 2009 | herpes simplex infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB208141 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00057330 ↗ |
| Known as | HSV vaccine | “HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine” NCT00057330 ↗ |
| Modality | Vaccine | “candidate genital herpes vaccine” NCT00057330 ↗ |
| Route | Intramuscular | “Three doses of vaccine or control will be administered intramuscularly in the non-dominant deltoid on a 0, 1, and 6 month schedule” NCT00057330 ↗ |